BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250515
DTSTAMP:20260515T094303
CREATED:20250225T112204Z
LAST-MODIFIED:20250225T112204Z
UID:40566-1747008000-1747267199@www.pharmajournalist.com
SUMMARY:4th ALS Drug Development Summit
DESCRIPTION:The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly\, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile\, QurAlis’ clinical trials for QRL-101 and QRL-201 and innovations in biomarker platforms are reshaping the treatment landscape. \nJoin 200+ scientific leaders in Boston to tackle key challenges in target validation\, biomarker development\, and clinical trial optimization—driving progress toward effective ALS and FTD therapies. \nTo know more visit: https://ter.li/48rlwg
URL:http://www.pharmajournalist.com/event/4th-als-drug-development-summit/
LOCATION:Revere\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR